Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

66.39
+0.06000.09%
Post-market: 66.390.00000.00%19:30 EDT
Volume:531.07K
Turnover:35.23M
Market Cap:3.20B
PE:-27.60
High:67.16
Open:66.23
Low:64.00
Close:66.33
52wk High:72.64
52wk Low:9.63
Shares:48.16M
Float Shares:27.63M
Volume Ratio:1.07
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4052
EPS(LYR):-2.3824
ROE:-33.17%
ROA:-22.08%
PB:7.81
PE(LYR):-27.87

Loading ...

Company Profile

Company Name:
MBX Biosciences
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
63
Office Location:
11711 North Meridian Street,Suite 300,Carmel,Indiana,United States
Zip Code:
46032
Fax:
- -
Introduction:
MBX Biosciences, Inc. was incorporated in August 2018 as an Indiana limited liability company and converted to a Delaware corporation in April 2019. The company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapeutics for endocrine and metabolic disorders. Its pipeline includes drug candidates for hypoparathyroidism, obesity, and post-bariatric hypoglycemia, designed using its proprietary Precision Endocrine Peptide (PEP) platform.

Directors

Name
Position
P. Kent Hawryluk
President, Chief Executive Officer and Director
Laurie Stelzer
Independent Director
Patrick Heron
Lead Independent Director
Steven Hoerter
Director and Executive Chairperson
Edward T. Mathers
Director
Ora Pescovitz
Director
Steven Ryder
Director
Tiba Aynechi
Director

Shareholders

Name
Position
P. Kent Hawryluk
President, Chief Executive Officer and Director
Richard Bartram
Chief Financial Officer
Salomon Azoulay
Chief Medical Officer